Coherus BioSciences - CHRS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.83
  • Forecasted Upside: 362.48%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.1 (-4.98%)

This chart shows the closing price for CHRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coherus BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRS

Analyst Price Target is $8.83
▲ +362.48% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Coherus BioSciences in the last 3 months. The average price target is $8.83, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 362.48% upside from the last price of $1.91.

This chart shows the closing price for CHRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Coherus BioSciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
5/13/2024Truist FinancialLower TargetBuy ➝ Buy$8.00 ➝ $7.00Low
5/10/2024HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $12.00Low
3/20/2024HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $11.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
1/23/2024Robert W. BairdLower TargetOutperform ➝ Outperform$11.00 ➝ $9.00Low
1/23/2024Truist FinancialLower TargetBuy ➝ Buy$12.00 ➝ $8.00Low
12/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
11/28/2023Truist FinancialReiterated RatingBuy ➝ Buy$12.00Low
11/17/2023Robert W. BairdInitiated CoverageOutperform$11.00Low
11/8/2023Maxim GroupDowngradeBuy ➝ HoldLow
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $13.00Low
10/23/2023BarclaysLower TargetOverweight ➝ Overweight$8.00 ➝ $7.00Low
10/12/2023Bank of AmericaLower Target$7.00 ➝ $6.00Low
9/26/2023Truist FinancialReiterated RatingBuy ➝ Buy$20.00Low
9/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
8/3/2023HC WainwrightLower TargetBuy ➝ Buy$24.00 ➝ $20.00Low
7/24/2023CitigroupInitiated CoverageBuy$12.00Low
7/14/2023Truist FinancialLower TargetBuy$22.00 ➝ $20.00Low
6/20/2023Truist FinancialLower Target$24.00 ➝ $22.00Low
5/23/2023BarclaysLower Target$13.00 ➝ $8.00Low
5/12/2023Maxim GroupLower Target$15.00 ➝ $12.00Low
5/9/2023HC WainwrightLower Target$26.00 ➝ $24.00Low
5/1/2023Truist FinancialInitiated CoverageBuy$24.00Low
3/28/2023UBS GroupUpgradeNeutral ➝ Buy$11.00Low
3/14/2023MizuhoBoost Target$21.00 ➝ $23.00Low
3/8/2023BarclaysLower TargetOverweight$15.00 ➝ $13.00Low
3/7/2023HC WainwrightLower TargetBuy$30.00 ➝ $26.00Low
11/17/2022Maxim GroupLower Target$15.00Low
11/16/2022MizuhoLower TargetBuy$28.00 ➝ $21.00Low
11/14/2022JPMorgan Chase & Co.Lower TargetNeutral$13.00 ➝ $11.00Low
8/16/2022MizuhoBoost TargetBuy$25.00 ➝ $28.00Low
6/13/2022UBS GroupInitiated CoverageNeutral$7.00High
5/20/2022MizuhoLower TargetBuy$30.00 ➝ $25.00High
5/9/2022BarclaysLower Target$20.00 ➝ $15.00High
5/3/2022HC WainwrightReiterated RatingBuy$30.00Low
3/23/2022MizuhoReiterated RatingBuy$30.00High
3/7/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $15.00Low
2/22/2022BarclaysLower Target$24.00 ➝ $20.00High
2/7/2022JPMorgan Chase & Co.Lower Target$23.00 ➝ $20.00High
11/9/2021HC WainwrightLower TargetBuy$36.00 ➝ $30.00High
10/6/2021HC WainwrightReiterated RatingBuy$36.00Low
8/6/2021Maxim GroupInitiated CoverageBuy$22.00Medium
7/23/2021HC WainwrightBoost TargetBuy$26.00 ➝ $36.00High
5/17/2021BarclaysLower TargetOverweight$28.00 ➝ $24.00High
5/13/2021HC WainwrightLower TargetBuy$29.00 ➝ $26.00Low
5/7/2021Maxim GroupInitiated CoverageBuy$22.00Low
5/7/2021HC WainwrightLower TargetBuy$28.00 ➝ $26.00High
2/25/2021CitigroupLower Target$30.00 ➝ $27.00High
2/25/2021HC WainwrightLower TargetBuy$33.00 ➝ $29.00High
11/19/2020MizuhoLower TargetBuy$35.00 ➝ $30.00Low
11/6/2020HC WainwrightLower TargetBuy$33.00 ➝ $32.00High
8/7/2020Maxim GroupInitiated CoverageBuy$27.00High
8/7/2020HC WainwrightBoost TargetBuy$30.00 ➝ $33.00Medium
7/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
5/9/2020Maxim GroupInitiated CoverageBuy$27.00Medium
5/8/2020HC WainwrightReiterated RatingBuy$30.00High
4/17/2020SunTrust BanksInitiated CoverageBuy$26.00High
3/5/2020Credit Suisse GroupReiterated RatingBuy$36.00Low
2/29/2020Maxim GroupReiterated RatingBuy$27.00High
2/28/2020HC WainwrightBoost TargetBuy$29.00 ➝ $30.00High
2/6/2020JPMorgan Chase & Co.Boost TargetOverweight$33.00 ➝ $35.00Medium
2/4/2020MizuhoReiterated RatingBuy$43.00High
11/27/2019MizuhoInitiated CoverageBuy$43.00Medium
11/25/2019HC WainwrightReiterated RatingBuy$29.00Low
11/8/2019Credit Suisse GroupReiterated RatingBuy$36.00Low
9/29/2019MizuhoSet TargetBuy$43.00Medium
8/13/2019MizuhoInitiated CoverageBuy ➝ Buy$43.00Medium
8/12/2019BarclaysSet TargetBuy$31.00Low
8/2/2019Maxim GroupReiterated RatingBuy ➝ Buy$25.00 ➝ $27.00High
8/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $29.00High
7/10/2019Maxim GroupReiterated RatingBuy$25.00Low
6/21/2019BarclaysSet TargetBuy$30.00Low
6/19/2019Robert W. BairdSet TargetBuy$28.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$30.00Medium
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.91
Low: $1.90
High: $2.03

50 Day Range

MA: $2.21
Low: $1.90
High: $2.51

52 Week Range

Now: $1.91
Low: $1.43
High: $5.63


1,444,600 shs

Average Volume

3,309,576 shs

Market Capitalization

$219.13 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Coherus BioSciences?

The following equities research analysts have issued research reports on Coherus BioSciences in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., HC Wainwright, Maxim Group, Robert W. Baird,, and Truist Financial Co..
View the latest analyst ratings for CHRS.

What is the current price target for Coherus BioSciences?

6 Wall Street analysts have set twelve-month price targets for Coherus BioSciences in the last year. Their average twelve-month price target is $8.83, suggesting a possible upside of 362.5%. HC Wainwright has the highest price target set, predicting CHRS will reach $12.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for Coherus BioSciences in the next year.
View the latest price targets for CHRS.

What is the current consensus analyst rating for Coherus BioSciences?

Coherus BioSciences currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CHRS.

What other companies compete with Coherus BioSciences?

Other companies that are similar to Coherus BioSciences include Compugen, Humacyte, Scholar Rock, Prime Medicine and CARGO Therapeutics. Learn More about companies similar to Coherus BioSciences.

How do I contact Coherus BioSciences' investor relations team?

Coherus BioSciences' physical mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company's listed phone number is (650) 649-3530 and its investor relations email address is [email protected]. The official website for Coherus BioSciences is Learn More about contacing Coherus BioSciences investor relations.